Dexcom Gets FDA Clearance of New Dexcom G6 Pro CGM

Published on
By : dLife Editors

Dexcom, Inc. announced today the U.S. FDA has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up.

Dexcom G6 Pro is the first and only single-use, professional CGM that gathers real-time glucose data over a 10-day period and offers both a blinded and unblinded mode.

In blinded mode, real-time glucose data is hidden from the patient and reviewed retrospectively with their healthcare professional at the end of the session.

In unblinded mode, patients can see their glucose data throughout the 10-day sensor wear to gain insights and make treatment decisions in real-time.

Regardless of mode, glucose data gathered by the Dexcom G6 Pro enables providers to adjust a patient’s diabetes therapy plan with precision and customization.

Providers can also use the data to help patients modify their daily behavior after seeing the effects that variables such as food, exercise, stress, and medication have on glucose levels.

“Dexcom G6 Pro will enable healthcare providers to set up their patients with CGM in minutes,” said Davida Kruger, MSN, APN-BC, BC-ADM, diabetes specialist, Division of Endocrinology, Diabetes, Bone and Mineral Disorders at Henry Ford Health System in Detroit.

“This new professional system will serve as a simple way to obtain data from CGM naïve patients who need glucose insight, but don’t need or want to be monitored around the clock,” he added.

Kruger said it will also give his patients a chance to try the Dexcom G6 Pro under a healthcare provider’s supervision before they commit to a personal system.

The company expects to begin shipping Dexcom G6 Pro early next year. For more information, visit


  1. Dexcom. (2019, October 8). Dexcom Announces FDA Clearance of New Dexcom G6 Pro CGM. BusinessWire. Retrieved October 8, 2019, from